Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS) - 27/01/21
Abstract |
Lactation is contraindicated for women with sickle cell anemia receiving hydroxyurea therapy, despite sparse pharmacokinetics data. In 16 women who were lactating volunteers, we documented hydroxyurea transferred into breastmilk with a relative infant dosage of 3.4%, which is below the recommended 5%-10% safety threshold. Breastfeeding should be permitted for women taking daily oral hydroxyurea.
Le texte complet de cet article est disponible en PDF.Keywords : hydroxyurea, sickle cell anemia, breastfeeding, pharmacokinetics
Abbreviations : PK, RID, SCA
Plan
Supported by the Cincinnati Children's Research Foundation. R.W. has received hydroxyurea donations from Bristol-Myers Squibb and Addmedica for use in other clinical trials, and serves on the Advisory Board for Global Blood Therapeutics, Agios, and Nova Laboratories. The authors declare no conflicts of interest. |
Vol 222
P. 236-239 - juillet 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?